The Art and Science of Managing the New Melanoma Landscape

The Art and Science of Managing the New Melanoma Landscape: 6th Annual Collaborative Conference is organized by The University of Texas MD Anderson Cancer Center and will be held from Sep 20 - 21, 2019 at Houston Marriott Medical Center/Museum District, Houston, Texas, United States of America.

Target Audience:
This conference should be of value to medical oncologists, surgical oncologists, dermatologists, nurse practitioners, scientists/researchers and other healthcare providers managing patients with melanoma.

Accreditation/Credit Designation Information:
Physicians:
The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 10.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Goal:
There has been rapid and exciting progress in the development of targeted, immune and intralesional therapies for melanoma. We now have many therapeutic options that did not exist only a few years ago. Thus, it can be challenging to determine which new therapy is the best to use in a heterogeneous population of patients. This conference will discuss the optimal treatment approaches for different presentations of early and advanced melanoma to facilitate the optimization and personalization of patient management for this disease.

Objectives:
After attending this conference, participants should be able to:
• Utilize the latest criteria and clinical evidence for treatment options for melanoma patients with clinically localized disease and interpret the components of the updated AJCC staging system for melanoma (Knowledge, Competence, Performance, Patient Outcomes);
• Make evidence-based decisions about the use of adjuvant immune and targeted therapies in patients with surgically resected stage III disease (Knowledge, Competence, Performance, Patient Outcomes);
• Make evidence-based decisions about the optimal selection and use of immunotherapy and targeted therapy in patients with stage IV metastatic disease (Knowledge, Competence, Performance, Patient Outcomes);
• Understand how to diagnose and treat toxicities from current systemic therapies for advanced melanoma patients (Knowledge);
• Understand the current data about the role of different treatment modalities, including immune and targeted therapies, in patients with brain metastases and with non-cutaneous melanomas (Knowledge);
• Understand the current data about the role of immunotherapy in the management of patients with non-melanoma skin cancer, including cutaneous squamous cell carcinoma and Merkel cell carcinoma (Knowledge).

Additional details will be posted as soon as they are available.